Will giritinib (segatan) cause nausea and vomiting and relief options

Gilteritinib (Gilteritinib, trade name: Xospata) is an oral FLT3 inhibitor, mainly used for FLT3Mutation-positive relapsed or refractory acute myeloid leukemia (AML). In clinical application, nausea and vomiting are common adverse reactions, especially in the initial stage of treatment or dose adjustment stage. Most patients have mild to moderate symptoms, but a small number may affect their daily diet and quality of life.

Giritinib causes nausea and vomiting, which is mainly related to the local irritation of the drug to the gastrointestinal tract and the mild impact on the central vomiting center. At the same time, when patients receive giritinib treatment, accompanied by chemotherapy or underlying diseases, gastrointestinal discomfort may also be aggravated. Symptoms usually peak within 1 to 2 weeks of taking the medication, but most can be alleviated through intervention.

For nausea and vomiting, various methods can be adopted, such as drug intervention, dose adjustment, and lifestyle management. Doctors can use 5-HT3 antagonists (such as ondansetron) and dopamine receptor antagonists to relieve symptoms in the short term; for those with severe intolerance, they can temporarily reduce the dose or extend the medication interval. The daily diet should be small and frequent, light and easy to digest, and keep plenty of water to help relieve gastrointestinal discomfort.

During treatment, patients should closely observe changes in gastrointestinal symptoms and promptly report persistent or worsening nausea, vomiting, and loss of appetite to the doctor. Elderly patients or those with chronic diseases should pay attention to water and electrolyte balance and nutritional support. Avoid stopping or increasing the dosage on your own to ensure efficacy and safety. With reasonable medication management and daily intervention, most patients can successfully complete the course of giritinib treatment.

Reference materials:https://www.drugs.com/